[15] Moreover, growing clinical data suggest that blinatumomab could be successfully used as a bridge therapy to allogeneic hematopoietic stem cell transplantation (HSCT) for r/r BCP-ALL patients [8,16]. The gene discussed is OPN1SW; the disease is acute lymphoblastic leukemia.